Clinical Study on the Treatment of MAFLD With Ganzhixiao Capsules

Dong Hui

Status and phase

Not yet enrolling

Phase 2

Conditions

MAFLD

Treatments

Drug: placebo capsule

Drug: ganzhixiao capsule

Study type

Interventional

Funder types

Other

Identifiers

NCT06848907

TJ-IRB202504027

Details and patient eligibility

About

This trial is expected to enroll 138 MAFLD patients in one clinical center, who will be randomly divided into a placebo group and a Ganzhixiao capsule group in a 1:1 ratio. There will be 69 patients in the Ganzhixiao group and 69 patients in the placebo group. Administer Ganzhixiao capsules or mimetics separately, intervene for 16 weeks, and compare the liver fat content、 ALT、 Changes in indicators such as cytokeratin 18 fragment, FIB-4 score, and LSM score. Among them, MRI-PDFF is the main efficacy evaluation index to evaluate the clinical efficacy of Ganzhixiao capsules in the treatment of MAFLD.

Full description

All participants in the trial were required to have a low-fat diet and engage in aerobic exercise for 150 minutes per week.

Enrollment

138 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age between 18 and 70 years old, with a body mass index (BMI) of at least 24kg/m2;
Diagnosis of NAFLD determined by imaging [ultrasound, computed tomography or magnetic resonance imaging (MRI-PDFF)] or liver biopsy, showing MAFLD or simple steatosis within the last 24 months prior to screening;
MAFLD patients conform to the damp heat syndrome type; ④ Voluntary signing of informed consent form

Exclusion criteria

Blood biochemical indicators ALT, AST, BUN are greater than 1.5 times the upper limit of normal values, Cr is greater than the upper limit of normal values, eGFR<60ml/min/1.73m2;
Alcoholic fatty liver, other chronic liver diseases, cirrhosis, liver malignant tumors, etc.;
Type 2 diabetes and pancreatic diseases;
Taking some hypoglycemic, lipid-lowering, liver protective drugs or high-dose vitamin E that may affect the efficacy judgment in the past three months;
Patients with severe infections, cardiovascular, respiratory, renal, hematological, rheumatic connective tissue disease, neuropsychiatric, and non liver malignant tumors;
Pregnant or lactating women;
Those who require long-term hormone therapy;
Researchers anticipate poor compliance or inability to cooperate;
There are contraindications for MRI examination, including pacemakers or cochlear implants, postoperative artificial valve replacement, presence of ferromagnetic vascular clips in the body, metal foreign bodies in the eyeball, insulin pumps, ferromagnetic objects in the scanning field, metal dentures, intrauterine devices, and patients with claustrophobia.